UE LifeSciences
UE LifeSciences develops innovative cancer screening technologies, including the iBreastExam and cervAIcal devices, and has recently introduced Selfi, an at-home breast health monitoring platform.
Services
UE LifeSciences offers innovative healthcare solutions for cancer screening, primarily focusing on breast and cervical cancer. The company has developed several advanced devices like iBreastExam, which is used for breast cancer screening, and cervAIcal, an AI-enabled mobile colposcope for cervical cancer screening. These technologies aim to provide accessible and affordable cancer screening services to a broad population.
Products
UE LifeSciences has developed and commercialized multiple pioneering products. iBreastExam is a radiation-free, ultra-portable wireless device for breast cancer screening that has received FDA clearance. The company is also behind cervAIcal, an AI-enabled mobile colposcope for cervical cancer screening which is currently in pilot studies. Additionally, UE LifeSciences introduced Selfi, an at-home breast health monitoring device based on iBreastExam technology, set for commercial launch in 2022.
Market Presence
UE LifeSciences has an extensive market presence, having entered 10 markets globally. The company has conducted over 2 million breast exams and has detected over 500 cancers through its screening initiatives. With a significant reach, the firm has offices in Philadelphia, USA; Mumbai, Bangalore, Delhi, India; and Kuala Lumpur, Malaysia, reflecting its strong international footprint.
Funding and Awards
UE LifeSciences has raised over $8.5 million in capital and has also received more than $1.7 million in grant awards. The company's innovative solutions and impactful services have been recognized through over 15 awards, highlighting its contributions to the healthcare industry.